Mocetinostat(MGCD0103)
编号: 111015
Cas号: 726169-73-9
纯度: 98% by HPLC/HNMR
Mocetinostat is an orally-bioavailable, spectrum-selective HDAC inhibitor. Mocetinostat has completed 13 clinical trials in more than 400 patients with a variety of hematologic malignancies and solid tumors. Mirati is currently conducting Phase 2 studies of mocetinostat as a single agent in patients with bladder cancer and DLBCL.
Mirati retains worldwide rights to mocetinostat with the exception of certain Asian territories where the program is partnered with Taiho.
仅供研究使用。 我们不向患者出售。
化学信息
| 名称 | Mocetinostat(MGCD0103) |
|---|---|
| Iupac 化学名称 | N-(2-Aminophenyl)-4-([[4-(pyridin-3-yl)pyrimidin-2-yl]amino]methyl)benzamide |
| 分子式 | C23H20N6O |
| 分子量 | 396.44 |
| Smile | O=C(NC1=CC=CC=C1N)C2=CC=C(CNC3=NC=CC(C4=CC=CN=C4)=N3)C=C2 |
| InChiKey | HRNLUBSXIHFDHP-UHFFFAOYSA-N |
| InChi | InChI=1S/C23H20N6O/c24-19-5-1-2-6-21(19)28-22(30)17-9-7-16(8-10-17)14-27-23-26-13-11-20(29-23)18-4-3-12-25-15-18/h1-13,15H,14,24H2,(H,28,30)(H,26,27,29) |
| Cas号 | 726169-73-9 |
| 相关CAS号 |
订购信息
| 包装 | 价格 | 库存 | 纯度 | 备货期 |
|---|---|---|---|---|
| 大货 | 询价 | 询价 | 询价 |
-cas-726169-73-9.png)